No Data
No Data
Atom Therapeutics and China Medical System Holdings Enter Exclusive Commercialization Agreement for Lingdolinurad (ABP-671) to Treat Chronic Gout and Hyperuricemia
Market bullish stimulus boosts Hong Kong pharmaceutical stocks, with Genshuo Niaoyao rising over 14%.
① What bullish impacts does the medical insurance centralized procurement have on pharmaceutical companies? ② How do institutions view the subsequent development of pharmaceutical stocks?
China Medical System Holdings Insider Ups Holding During Year
Zhitong Hong Kong stocks early to know | The People's Bank of China revised the M1 statistics caliber. The total value of Hong Kong's overall building transaction registration in November hit a new high in 4 months.
HKEX (00388) Global Listing Services Director Xu Jingwei pointed out at the opening forum of the 9th China Biomedical Innovation and Investment Conference that HKEX continues to play an important role in assisting global biomedical companies in listing and financing.
cms (00867.HK) has obtained exclusive commercialization rights for a Class 1 new drug for the treatment of gout and hyperuricemia.
GeLongHui December 2nd | CMS (00867.HK) announced that on December 2, 2024, the group signed an exclusive commercialization agreement through its wholly-owned subsidiary with Hangzhou New Element Pharmaceutical Co., Ltd. on a new class 1 drug ABP-671 for the treatment of gout and hyperuricemia. According to the agreement, the group obtained the exclusive commercialization rights of the product in Mainland China, Hong Kong Special Administrative Region, and Macau Special Administrative Region. The collaboration period starts from the effective date of the agreement, with a ten-year authorization period starting from the first listing of the product in Mainland China. After the authorization period expires, according to specific conditions agreed in the agreement, the authorization period may
Express News | China Medical System - Deal for Commercialization of Class 1 Innovative Drug Abp-671 for Treatment of Gout & Hyperuricemia
No Data